Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 935-943

  Fujisaka, Yasuhito ^a   Yamada, Yasuhide ^a   Yamamoto, Noboru ^a   Shimizu, Toshio ^a   Fujiwara, Yutaka ^a   Yamada, Kazuhiko ^a   Tamura, Tomohide ^a   Watanabe, Hiroyuki ^b   Sun, Yu Nien ^c   Bass, Michael B ^c   Seki, Mitsuo ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Takeda Bio Development Center Ltd   (Japan)

^c AMGEN INC   (United States)

Author keywords

Advanced solid tumors; Maximum tolerated dose; Motesanib; Pharmacokinetics

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; MOTESANIB;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; EOSINOPHILIA; EYELID EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEMATURIA; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; JAPANESE; LEUKOPENIA; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH CANCER; STOMACH DISCOMFORT; THYMOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; JAPAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NIACINAMIDE; TREATMENT OUTCOME;

EID: 77956225558     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1243-y     Document Type: Article

References (29)

1. Kato H, Sobue T, Katanoda K et al (2007) Cancer statistics in Japan 2007. National Cancer Center, Tokyo
2. J Folkman 2002 Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 15 18 1:CAS:528:DC%2BD3sXlvFSqtg%3D%3D 12516034
3. S Arii 2006 Tumor angiogenesis and antiangiogenic therapy: current status and perspective Int J Clin Oncol 11 71 72 10.1007/s10147-006-0569-2 16622741
4. LM Ellis DJ Hicklin 2008 VEGF-targeted therapy: mechanism of anti-tumour activity Nat Rev Cancer 8 579 591 10.1038/nrc2403 1:CAS:528:DC%2BD1cXovV2lsro%3D 18596824
5. TJ Abrams LJ Murray E Pesenti, et al. 2003 Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer Mol Cancer Ther 2 1011 1021 1:CAS:528:DC%2BD3sXosVCqsb8%3D 14578466
6. LJ Wilmes MG Pallavicini LM Fleming, et al. 2007 AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging Magn Reson Imaging 25 319 327 10.1016/j.mri.2006.09. 041 1:CAS:528:DC%2BD2sXjtVagur0%3D 17371720
7. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 10.1158/0008-5472.CAN-04-1443 1:CAS:528:DC%2BD2cXotFalsbk%3D 15466206
8. SR Wedge DJ Ogilvie M Dukes, et al. 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645 4655 1:CAS:528:DC%2BD38XmsVShsL8%3D 12183421
9. RJ Motzer BI Rini RM Bukowski, et al. 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524 10.1001/jama.295.21.2516 1:CAS:528:DC%2BD28XlsV2rtLk%3D 16757724
10. RS Herbst A Onn A Sandler 2005 Angiogenesis and lung cancer: prognostic and therapeutic implications J Clin Oncol 23 3243 3256 10.1200/JCO.2005.18.853 1:CAS:528:DC%2BD2MXltVWis7k%3D 15886312
11. HS Rugo RS Herbst G Liu, et al. 2005 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 5474 5483 10.1200/JCO.2005.04.192 1:CAS:528:DC%2BD2MXhtVersr7F 16027439
12. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI 17167137
13. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676 10.1038/nm0603-669 1:CAS:528:DC%2BD3sXktFOnur4%3D 12778165
14. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 932 936 10.1038/nature04478 1:CAS:528:DC%2BD2MXhtlSksrjF 16355210
15. J Yu C Ustach HR Kim 2003 Platelet-derived growth factor signaling and human cancer J Biochem Mol Biol 36 49 59 1:CAS:528:DC%2BD3sXhtV2isb8%3D 12542975
16. D Wang HJ Huang A Kazlauskas WK Cavenee 1999 Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase Cancer Res 59 1464 1472 1:CAS:528:DyaK1MXisVWktb8%3D 10197615
17. A Polverino A Coxon C Starnes, et al. 2006 AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Res 66 8715 8721 10.1158/0008-5472.CAN-05-4665 1:CAS:528:DC%2BD28XovF2hs7w%3D 16951187
18. LS Rosen R Kurzrock M Mulay, et al. 2007 Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors J Clin Oncol 25 2369 2376 10.1200/JCO.2006.07.8170 1:CAS:528:DC%2BD2sXns1KmtL0%3D 17557949
19. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
20. S Faivre C Delbaldo K Vera, et al. 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35 10.1200/JCO.2005.02. 2194 1:CAS:528:DC%2BD28Xot1ChtQ%3D%3D 16314617
21. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435
22. JC Yang L Haworth RM Sherry, et al. 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 10.1056/NEJMoa021491 1:CAS:528: DC%2BD3sXms1Klu7w%3D 12890841
23. A Bouloumie VB Schini-Kerth R Busse 1999 Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells Cardiovasc Res 41 773 780 10.1016/S0008-6363(98)00228-4 1:CAS:528: DyaK1MXhvVGhtLY%3D 10435050
24. B Pankaj 2009 VEGF kinase inhibitors: how do they cause hypertension Am J Physiol Regul Integr Comp Physiol 297 R1 R5
25. R Basser H Hurwitz A Barge, et al. 2001 Phase 1 pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors Proc Am Soc Clin Oncol 20 396
26. T Eisen T Ahmad ME Gore, et al. 2005 Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. (#7508) Proc Am Soc Clin Oncol 23 16S
27. M Kulke HJ Lenz NJ Meropol, et al. 2005 A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors. (#4008) Proc Am Soc Clin Oncol 23 16S
28. MA Shah D Ilson DP Kelson 2005 Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan and bevacizumab-based therapy J Clin Oncol 11 2574 2576 10.1200/JCO.2005.81.908
29. M Zangari E Anaisse B Barlogie, et al. 2001 Increased risk of deep venous thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Blood 98 1614 1615 10.1182/blood.V98.5.1614 1:CAS:528: DC%2BD3MXmvFGjur8%3D 11520815